BioSpace News Archive

The bioscience industry provides direct and indirect employment of 47,000 jobs in Oregon, showing substantial growth in the past decade.

Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointment of Brian C. Bock as the Company’s Chief Financial Officer (CFO) effective immediately.

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, announced that China’s National Medical Products Administration

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the SEQuoia RiboDepletion Kit, which improves assay efficiency by eliminating irrelevant ribosomal RNA (rRNA) fragments from an RNA-Seq library.

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Today, Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) successfully hosted an inauguration ceremony for its manufacturing center at the Binhai Life Science and Healthcare Industrial Zone in Shaoxing.

Vera Therapeutics, Inc. (“Vera”), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of $11.00 per share

As the world joins together to fight the ongoing battle against the COVID-19 pandemic, Terumo Corporation has announced that the Terumo Group companies will collectively donate USD 1 million in cash to support the COVID-19 Solidarity Response Fund for the World Health Organization.

Australian pharmaceutical group Phebra congratulates the Australasian Leukaemia and Lymphoma Group on the release of their abstract EP433 at the virtual European Hematology Association 2021 Conference.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.25 per share.